Mechanisms of Immune Activation and Inflammation: HIV Infection, ART, and Drugs of Abuse (R01)
The summary for the Mechanisms of Immune Activation and Inflammation: HIV Infection, ART, and Drugs of Abuse (R01) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Mechanisms of Immune Activation and Inflammation: HIV Infection, ART, and Drugs of Abuse (R01): The purpose of this FOA is to promote research to investigate the underlying molecular mechanisms of HIV infection-induced immune activation and inflammation in the presence of antiretroviral therapy (ART) agents and drugs of abuse. The ultimate goal is to obtain information for developing therapeutic interventions for attenuating chronic inflammation-associated comorbidities as well as for restoring or improving ART efficacy in HIV-infected drug-abusing populations.
|Federal Grant Title:||Mechanisms of Immune Activation and Inflammation: HIV Infection, ART, and Drugs of Abuse (R01)|
|Federal Agency Name:||National Institutes of Health (HHS-NIH11)|
|Grant Categories:||Education Health|
|Type of Opportunity:||Discretionary|
|Funding Opportunity Number:||RFA-DA-17-013|
|Type of Funding:||Grant|
|CFDA Descriptions:||Information not provided|
|Current Application Deadline:||November 18th, 2016|
|Original Application Deadline:||November 18th, 2016|
|Posted Date:||July 28th, 2016|
|Creation Date:||July 28th, 2016|
|Archive Date:||December 19th, 2016|
|Total Program Funding:|
|Maximum Federal Grant Award:|
|Minimum Federal Grant Award:|
|Expected Number of Awards:|
|Cost Sharing or Matching:||No|
|Last Updated:||July 28th, 2016|
- Applicants Eligible for this Grant
- State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For-profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification.)
- Additional Information on Eligibility
- Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
- Link to Full Grant Announcement
- Grant Announcement Contact
- NIH OER Webmaster
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
- Similar Government Grants
- • Population Assessment of Tobacco and Health (PATH) Study Biospecimen Access (X01)
- • New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services (R01 Clinical Tria...
- • New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services (R34 - Clinical Tr...
- • NIDA Core "Center of Excellence" Grant Program (P30 Clinical Trial Optional)
- • Using Human Cell Animal Chimera Brains to Study HIV Latency and Pathology R01 - Clinical T...
- • NIDA Phase II Small Business Innovation Research (SBIR [R44]) Competing Renewal Awards
- • Drug Abuse Aspects of Hiv/Aids and Other Infections
- • Epidemiology of Drug Abuse
- More Grants from the National Institutes of Health
- • Integrative Neuroscience Initiative on Alcoholism (INIA) Consortia Administrative Resource...
- • Integrative Neuroscience Initiative on Alcoholism (INIA) Consortia Research Resource (U24)...
- • New Cohorts for Environmental Exposures and Cancer Risk (CEECR; UG3/UH3 Clinical Trial Not...
- • Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical ...
- • Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 Clinical Tria...